Literature DB >> 24935275

Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis.

Alexander C Ford1, Eamonn M M Quigley2, Brian E Lacy3, Anthony J Lembo4, Yuri A Saito5, Lawrence R Schiller6, Edy E Soffer7, Brennan M R Spiegel8, Paul Moayyedi9.   

Abstract

OBJECTIVES: Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder. Evidence relating to the treatment of this condition with antidepressants and psychological therapies continues to accumulate.
METHODS: We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs). MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to December 2013). Trials recruiting adults with IBS, which compared antidepressants with placebo, or psychological therapies with control therapy or "usual management," were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% confidence interval (CI).
RESULTS: The search strategy identified 3,788 citations. Forty-eight RCTs were eligible for inclusion: thirty-one compared psychological therapies with control therapy or "usual management," sixteen compared antidepressants with placebo, and one compared both psychological therapy and antidepressants with placebo. Ten of the trials of psychological therapies, and four of the RCTs of antidepressants, had been published since our previous meta-analysis. The RR of IBS symptom not improving with antidepressants vs. placebo was 0.67 (95% CI=0.58-0.77), with similar treatment effects for both tricyclic antidepressants and selective serotonin reuptake inhibitors. The RR of symptoms not improving with psychological therapies was 0.68 (95% CI=0.61-0.76). Cognitive behavioral therapy, hypnotherapy, multicomponent psychological therapy, and dynamic psychotherapy were all beneficial.
CONCLUSIONS: Antidepressants and some psychological therapies are effective treatments for IBS. Despite the considerable number of studies published in the intervening 5 years since we last examined this issue, the overall summary estimates of treatment effect have remained remarkably stable.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935275     DOI: 10.1038/ajg.2014.148

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  111 in total

Review 1.  ACG and CAG Clinical Guideline: Management of Dyspepsia.

Authors:  Paul Moayyedi; Brian E Lacy; Christopher N Andrews; Robert A Enns; Colin W Howden; Nimish Vakil
Journal:  Am J Gastroenterol       Date:  2017-06-20       Impact factor: 10.864

2.  Perceived Stress, Its Physiological Correlates, and Quality of Life in Patients With Irritable Bowel Syndrome.

Authors:  Kristen R Weaver; Gail D'Eramo Melkus; Jason Fletcher; Wendy A Henderson
Journal:  Biol Res Nurs       Date:  2018-02-05       Impact factor: 2.522

3.  Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome.

Authors:  Jeffrey M Lackner; James Jaccard; Laurie Keefer; Darren M Brenner; Rebecca S Firth; Gregory D Gudleski; Frank A Hamilton; Leonard A Katz; Susan S Krasner; Chang-Xing Ma; Christopher D Radziwon; Michael D Sitrin
Journal:  Gastroenterology       Date:  2018-04-25       Impact factor: 22.682

4.  Functional Somatic Symptoms.

Authors:  Casper Roenneberg; Heribert Sattel; Rainer Schaefert; Peter Henningsen; Constanze Hausteiner-Wiehle
Journal:  Dtsch Arztebl Int       Date:  2019-08-09       Impact factor: 5.594

5.  SYMPOSIUM REPORT: An Evidence-Based Approach to IBS and CIC: Applying New Advances to Daily Practice: A Review of an Adjunct Clinical Symposium of the American College of Gastroenterology Meeting October 16, 2016 • Las Vegas, Nevada.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-02

6.  Pilot Study of Functional Magnetic Resonance Imaging Responses to Somatic Pain Stimuli in Youth With Functional and Inflammatory Gastrointestinal Disease.

Authors:  Jeannie S Huang; Laura Terrones; Alan N Simmons; Walter Kaye; Irina Strigo
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-11       Impact factor: 2.839

7.  Ambivalence over emotional expression and perceived social constraints as moderators of relaxation training and emotional awareness and expression training for irritable bowel syndrome.

Authors:  Hannah J Holmes; Elyse R Thakur; Jennifer N Carty; Maisa S Ziadni; Heather K Doherty; Nancy A Lockhart; Howard Schubiner; Mark A Lumley
Journal:  Gen Hosp Psychiatry       Date:  2018-05-03       Impact factor: 3.238

8.  Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients.

Authors:  Benjamin Cassell; C Prakash Gyawali; Vladimir M Kushnir; Britt M Gott; Billy D Nix; Gregory S Sayuk
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

9.  Medical comorbidity and distress in patients with irritable bowel syndrome: The moderating role of age.

Authors:  Elyse R Thakur; Brian M Quigley; Hashem B El-Serag; Gregory D Gudleski; Jeffrey M Lackner
Journal:  J Psychosom Res       Date:  2016-07-16       Impact factor: 3.006

10.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.